117 results
Page 5 of 6
8-K
EX-99.1
93of9
2 Dec 19
Regulation FD Disclosure
7:03am
8-K
EX-99.1
tt1 oi5dnuht3c
24 Oct 19
62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence
8:36am
8-K
6ju3i7cj9qxov4i83
24 Oct 19
62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence
8:36am
8-K
e800pubogexznd
17 Oct 19
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
8:30am
8-K
EX-99.1
g34vg
17 Oct 19
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
8:30am
8-K
EX-99.2
lz03pcmbask5h30t33w
17 Oct 19
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
8:30am
8-K
EX-99.1
in4bfzde
24 Apr 19
Regulation FD Disclosure
8:31am
424B5
dom0kngtayoietrwzo
8 Apr 19
Prospectus supplement for primary offering
12:00am
8-K
EX-1.1
vghtuh3o
8 Apr 19
Entry into a Material Definitive Agreement
12:00am
424B5
2itg4oq
8 Apr 19
Prospectus supplement for primary offering
12:00am
8-K
EX-1.2
ta254uv8su
8 Apr 19
Entry into a Material Definitive Agreement
12:00am
424B5
w1ib3
4 Apr 19
Prospectus supplement for primary offering
4:15pm
424B5
fj67avel5u8mfmdj6g
4 Apr 19
Prospectus supplement for primary offering
4:13pm
8-K
EX-10.1
x2tsg bulhxwyi
11 Jan 19
Entry into a Material Definitive Agreement
5:02pm